# EDGAR Filing Document

**Accession Number:** 0001682638
**File Stem:** 0001682638-26-000002
**Filing Date:** 2026-1
**Character Count:** 21382
**Document Hash:** bc9d7b09b9b7639fead359f1da93e995
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001682638-26-000002.hdr.sgml**: 20260102

**ACCESSION NUMBER**: 0001682638-26-000002

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260102

**DATE AS OF CHANGE**: 20260102

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92777
- **FILM NUMBER:** 26503497

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FAIRBAIRN EMILY
- **CENTRAL INDEX KEY:** 0001682638

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 10 ORINDA VIEW ROAD
- **CITY:** ORINDA
- **STATE:** CA
- **ZIP:** 94563

## Exhibit 99.1

**JOINT FILING AGREEMENT**

Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.

Dated: January 2, 2026

---

| | |
|:---|:---|
| By:  | &nbsp;&nbsp;&nbsp;/s/ Emily Fairbairn |
| Name: Emily Fairbairn | Name: Emily Fairbairn |
| By:  | &nbsp;&nbsp;&nbsp;/s/ Malcom Fairbairn |
| Name: Malcom Fairbairn | Name: Malcom Fairbairn |
|  **Malcom and Emily Fairbairn 2010 CRUT** | **Malcom and Emily Fairbairn 2010 CRUT** |
| By:  | &nbsp;&nbsp;&nbsp;/s/ Malcom Fairbairn |
| Name: Malcom Fairbairn | Name: Malcom Fairbairn |
| Title: Trustee | Title: Trustee |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**IN8BIO, INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**45674E208**

*(CUSIP Number)*

**Emily Fairbairn**<br>10 Orinda View Road<br>Orinda CA 94563<br>925-284-7777

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **45674E208** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**EMILY FAIRBAIRN** | Name of reporting person<br>**EMILY FAIRBAIRN** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**8656.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**724637.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**8656.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**724637.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**733293.00** | Aggregate amount beneficially owned by each reporting person<br>**733293.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.5%** | Percent of class represented by amount in Row (11)<br>**7.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **45674E208** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Malcom Fairbairn** | Name of reporting person<br>**Malcom Fairbairn** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3044.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**724637.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**3044.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**724637.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**727681.00** | Aggregate amount beneficially owned by each reporting person<br>**727681.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.5%** | Percent of class represented by amount in Row (11)<br>**7.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **45674E208** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Malcom and Emily Fairbairn 2010 CRUT** | Name of reporting person<br>**Malcom and Emily Fairbairn 2010 CRUT** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**724637.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**724637.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**724637.00** | Aggregate amount beneficially owned by each reporting person<br>**724637.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.4%** | Percent of class represented by amount in Row (11)<br>**7.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
IN8BIO, INC.

**(c) Address of Issuer's Principal Executive Offices:**
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the Common Stock for investment purposes. Except as set forth herein and except that the Reporting Persons may, from time to time or at any time, subject to market conditions and other factors, purchase additional Common Stock in the open market, in privately negotiated transactions or otherwise, or sell at any time all or a portion of the Common Stock now owned or hereafter acquired by them to one or more purchasers, as of the date of this Schedule 13D, the Reporting Persons do not have any present plans which relate to or would result in:

(a)	The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer (including by means of Rule 10b5-1 programs);

(b)	An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

(c)	A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d)	Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e)	Any material change in the present capitalization or dividend policy of the Issuer;

(f)	Any other material change in the Issuer's business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;

(g)	Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(h)	Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i)	A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j)	Any action similar to any of those enumerated above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, Ms. Fairbairn beneficially owns an aggregate of 733,293 shares of Common Stock, consisting of (a) 724,637 shares of Common Stock held directly by the CRUT, (b) Series C Warrants exercisable for up to 101,291 shares of Common Stock held directly by the CRUT, (c) Pre-Funded Warrants exercisable for up to 101,291 shares of Common Stock directly held by the CRUT, (d) 923 shares of Common Stock held by the Roth IRA, and (e) 7,733 shares of Common Stock underlying outstanding options that are immediately exercisable or will be immediately exercisable within 60 days of December 22, 2025. Ms. Fairbairn is a trustee of the CRUT and shares voting and investment power over the securities held by the CRUT.

As of the date hereof, Mr. Fairbairn beneficially owns an aggregate of 727,681 shares of Common Stock, consisting of (a) 724,637 shares of Common Stock held directly by the CRUT, (b) Series C Warrants exercisable for up to 101,291 shares of Common Stock held directly by the CRUT, (c) Pre-Funded Warrants exercisable for up to 101,291 shares of Common Stock directly held by the CRUT, and (d) 3,044 shares of Common Stock held by Valley High. Mr. Fairbairn is the sole managing partner of Valley High and has voting and investment power over the shares held by Valley High. Mr. Fairbairn is a trustee of the CRUT and shares voting and investment power over the securities held by the CRUT.

Each of the Series C Warrants and the Pre-Funded Warrants contains a provision (the "Beneficial Ownership Limitation") which precludes exercise of the Warrants to the extent that, following exercise, the holder, together with any other persons whose beneficial ownership of Common Stock could be aggregated with the holder's for purposes of the Exchange Act, would own more than 4.99% of the Common Stock outstanding, which percentage may be increased or decreased at the holder's election upon notice to the Issuer up to 19.99%. The CRUT is currently prohibited from exercising the Pre-Funded Warrants and the Series C Warrants by virtue of the Beneficial Ownership Limitation.

Each of Ms. Fairbairn and Mr. Fairbairn may be deemed to beneficially own 7.5% of the Issuer's outstanding Common Stock and the CRUT may be deemed to beneficially own 7.4% of the Issuer's outstanding Common Stock, which percentages are calculated based upon (a) 4,634,396 shares of Common Stock outstanding on November 3, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and (b) 5,127,029 shares of Common Stock issued by the Issuer in the Private Placement, as reported in the Issuer's Current Report on Form 8-K filed on December 19, 2025.

**(b)**
Ms. Fairbairn has sole voting and dispositive power over 8,656 shares of the Issuer's Common Stock. Mr. Fairbairn has sole voting and dispositive power over 3,044 shares of the Issuer's Common Stock. The Reporting Persons share voting and dispositive power over 724,637 shares of the Issuer's Common Stock.

**(c)**
Except as described herein, none of the Reporting Persons have purchased or sold any shares of Common Stock during the past 60 days.

2025 Securities Purchase Agreement

On December 18, 2025, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with the CRUT and other investors, pursuant to which the Issuer agreed to issue and sell shares (the "Shares") of the Issuer's Common Stock, and, in lieu of Common Stock, pre-funded warrants (the "2025 Pre-Funded Warrants" and, together with the Shares, the "Securities") to purchase shares of Common Stock (the "Warrant Shares"), in up to two closings in a private placement (the "Private Placement").

The initial closing (the "Initial Closing") of the Private Placement occurred on December 22, 2025. At the Initial Closing, the Issuer issued and sold to the CRUT and the other investors an aggregate of 5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share (the "Share Price"), and, in lieu of Common Stock, 2025 Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per 2025 Pre-Funded Warrant (the "Pre-Funded Warrant Price") for aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses.

Pursuant to the Purchase Agreement, subject to the occurrence of the Second Closing Trigger (as defined below), the Issuer also agreed to issue and sell to the CRUT and other investors in a second closing (the "Second Closing") up to an additional 14,579,706 Shares of Common Stock or 2025 Pre-Funded Warrants in lieu of Common Stock, at the Share Price and the Pre-Funded Warrant Price, respectively, for additional aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses. The Second Closing Trigger shall occur upon (i) the achievement, during the period commencing on the date of the Initial Closing and ending on December 31, 2026, of the presentation by the Issuer of animal model data for its INB-619 product candidate (the "INB-619 Milestone"), and (ii) either (A) the achievement of a volume weighted average price per share of equal to or greater than 200% of the Share Price (subject to appropriate, proportional adjustment for any stock splits or combinations of the Common Stock occurring after the date of the Purchase Agreement) measured during any five consecutive trading days during the 90 trading days following the date of the Issuer's first announcement via a press release or Current Report on Form 8-K of the occurrence of the INB-619 Milestone (such period the "Measurement Period" and such price threshold requirement, the "Price Threshold") or (b) the Issuer's receipt of a written notice signed by the investors holding a majority of the Securities outstanding from time to time and delivered to the Issuer during the Measurement Period that waives the Price Threshold for purposes of the Second Closing.

Pursuant to the Purchase Agreement, the Issuer may, at its sole discretion, elect to reduce the investors' committed investment amounts for the Second Closing, on a pro rata basis, by an amount equal to any cash proceeds received from any licensing, partnership or other collaboration agreements that are not attributable to the issuance of any equity or equity-linked securities. The Issuer also granted each investor the right until December 31, 2026 to participate in a subsequent equity financing of the Issuer up to 200% of the amount equal to such investor's investment amounts for the Initial Closing and Second Closing (as adjusted pursuant to the Issuer's reduction right described above).

The summary of the Purchase Agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as an exhibit hereto.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

2024 Securities Purchase Agreement

On September 30, 2024, the Issuer entered into a Securities Purchase Agreement (the "2024 Purchase Agreement") with the CRUT and other investors, pursuant to which the CRUT purchased Pre-Funded Warrants exercisable for up to 101,291 shares of Common Stock and Series C Warrants exercisable for up to 101,291 shares of Common Stock. The closing of the 2024 Purchase Agreement occurred on October 4, 2024.

The Pre-Funded Warrants have an exercise price of $0.003 per share. Each Pre-Funded Warrant is exercisable immediately and is exercisable until such Pre-Funded Warrant is exercised in full. In lieu of a cash payment to the Issuer in payment of the aggregate exercise price upon exercise of a Pre-Funded Warrant, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. The Pre-Funded Warrants are subject to the Beneficial Ownership Limitation.

The Series C Warrants have an exercise price of $8.10 per share. Each Series C Warrant is exercisable immediately and will expire three years from the date of issuance. The Series C Warrants are subject to the Beneficial Ownership Limitation.

2025 Securities Purchase Agreement

The description of the Purchase Agreement contained in Item 5(c) above is incorporated herein by reference.

Registration Rights Agreement

On December 18, 2025, the Issuer entered into a registration rights agreement (the "Registration Rights Agreement") with the CRUT and the other investors in the Private Placement pursuant to which the Issuer agreed to register for resale the Shares and the Warrant Shares (collectively, the "Registrable Securities"). Under the Registration Rights Agreement, the Issuer agreed to file a registration statement covering the resale by the CRUT and the other investors of the Registrable Securities no later than 30 days following the Initial Closing or Second Closing, as applicable.

The summary of the Registration Rights Agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as an exhibit hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** EMILY FAIRBAIRN

**Signature:** /s/ Emily Fairbairn

**Name/Title:** Emily Fairbairn

**Date:** 01/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Malcom Fairbairn

**Signature:** /s/ Malcom Fairbairn

**Name/Title:** Malcom Fairbairn

**Date:** 01/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Malcom and Emily Fairbairn 2010 CRUT

**Signature:** /s/ Malcom Fairbairn

**Name/Title:** Malcom Fairbairn, Trustee

**Date:** 01/02/2026